<DOC>
	<DOC>NCT00971243</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of MP-513 in combination with Metformin in patients with type 2 diabetes for 24 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with Metformin with an extension treatment for up to 52 weeks.</brief_summary>
	<brief_title>Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients who are aged ≧ 18 years old. Patients whose HbA1c is ≧ 7.0 % and ＜ 10.0%. Patients whose BMI is ≧ 20.0 and ≦40.0 ㎏/㎡. Patients who took metformin monotherapy for at least 56 consecutive days at the screening visit. Patients with type 1 diabetes or secondary form of diabetes. Patients with heart failure symptoms. Patients with serious diabetic complications. Patients with severe hepatic disorder or severe renal disorder. Patients who are the excessive alcohol addicts. Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Insulin resistance</keyword>
</DOC>